https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Hum. Immunol. 2010 Jan;71(1):67-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Hum. Immunol. 2010 Jan;71(1):67-732010-01-01 00:00:002019-02-15 08:44:09Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Methods Mol. Biol. 2010;595:149-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Methods Mol. Biol. 2010;595:149-632010-01-01 00:00:002019-02-15 08:44:11Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Immunotherapy 2010 Jan;2(1):57-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Immunotherapy 2010 Jan;2(1):57-682010-01-01 00:00:002019-02-15 08:45:16Personalized dendritic cell-based tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):139-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):139-572010-01-01 00:00:002019-02-15 08:46:45Dendritic cell vaccines for brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-109
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-1092010-01-01 00:00:002019-02-15 08:47:25Clinical applications of a peptide-based vaccine for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):195-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):195-92010-01-01 00:00:002019-02-15 08:59:37Monitoring immune responses after glioma vaccine immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-572010-01-01 00:00:002019-02-15 09:17:27Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-405
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-4052009-12-24 00:00:002009-12-24 00:00:00Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-15 / Clin. Cancer Res. 2009 Dec;15(24):7726-7736
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-15 / Clin. Cancer Res. 2009 Dec;15(24):7726-77362009-12-15 00:00:002019-02-15 08:46:08Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-01 / Endocr Metab Immune Disord Drug Targets 2009 Dec;9(4):328-43
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-01 / Endocr Metab Immune Disord Drug Targets 2009 Dec;9(4):328-432009-12-01 00:00:002019-02-15 08:44:08Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification
